Q2 EPS Estimates for AIM ImmunoTech Increased by Analyst

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) – Investment analysts at Ascendiant Capital Markets boosted their Q2 2026 EPS estimates for shares of AIM ImmunoTech in a research report issued to clients and investors on Sunday, May 31st. Ascendiant Capital Markets analyst E. Woo now anticipates that the company will post earnings of ($0.12) per share for the quarter, up from their prior forecast of ($0.37). Ascendiant Capital Markets currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for AIM ImmunoTech’s current full-year earnings is ($1.47) per share. Ascendiant Capital Markets also issued estimates for AIM ImmunoTech’s Q3 2026 earnings at ($0.12) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.63) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.13) EPS and FY2027 earnings at ($0.52) EPS.

AIM ImmunoTech (NYSEAMERICAN:AIM) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.69) earnings per share (EPS) for the quarter. The firm had revenue of $0.02 million for the quarter.

Separately, Zacks Research downgraded shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $9.00.

AIM ImmunoTech Stock Down 11.5%

Shares of AIM ImmunoTech stock opened at $0.73 on Thursday. The firm’s 50 day moving average price is $0.50 and its 200-day moving average price is $0.94. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.10. AIM ImmunoTech has a 52-week low of $0.21 and a 52-week high of $20.35. The company has a market cap of $10.66 million, a P/E ratio of -0.11 and a beta of 1.18.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Sabby Management LLC purchased a new stake in AIM ImmunoTech during the 3rd quarter worth approximately $79,000. DRW Securities LLC grew its position in AIM ImmunoTech by 60.6% during the 4th quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after purchasing an additional 26,254 shares during the last quarter. Finally, Corient Private Wealth LLC purchased a new stake in AIM ImmunoTech during the 2nd quarter worth approximately $87,000. Hedge funds and other institutional investors own 12.02% of the company’s stock.

Key AIM ImmunoTech News

Here are the key news stories impacting AIM ImmunoTech this week:

• Positive Sentiment: Ascendiant Capital Markets raised its earnings estimates for multiple future quarters and full-year periods, including FY2026 and FY2027, suggesting a more favorable outlook for AIM ImmunoTech’s loss trajectory and long-term earnings potential. AIM ImmunoTech analyst estimate revisions
• Positive Sentiment: The firm maintained a Buy rating and a $9.00 target price, which implies meaningful upside versus the stock’s current sub-$1 share price and may support investor optimism. AIM ImmunoTech analyst target price

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.